Efficacy and Safety of Prolonged Treatment with Pemafibrate plus an HMG-CoA Reductase Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus
Drug Research · 01.09.2025 · 75 (07) · 275-280
DOI: 10.1055/a-2560-9750 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Research, erschienen am 01.09.2025. Verfasst von Masataka Kusunoki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Motor Function and Metabolism, Research Center of Health, Physical Fitness and Sports, Nagoya University, Chikusa-ku, Nagoya …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Benzoxazoles, Butyrates. Die Arbeit nennt 12 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
It has been suggested that caution should be exercised when using HMG-CoA reductase inhibitor (statin) in combination with a drug of the fibrate family because of the potentially elevated risk of development of hepatic function impairment and myopathy. We conducted this present study to evaluate the efficacy and safety of treatment with a statin plus pemafibrate (a new fibrate) versus treatment with pemafibrate alone in Japanese patients with type 2 diabetes mellitus. In this study, a total of 23 Japanese patients with type 2 diabetes mellitus were divided into two groups: a group that received pemafibrate alone and a group that received pemafibrate+a statin for a period of 3 years, respectively. Blood levels of lipids and hepatic and renal function parameters were measured before and one and three years after the start of treatment. The pemafibrate-alone group showed reduction of the blood lipid levels, but no adverse changes of the hepatic or renal function parameters were observed. Similarly, the combined pemafibrate+statin treatment group also showed lowering of the blood lipid levels without any adverse changes of the parameters. Improvement of the blood lipid profile was observed in patients who received prolonged treatment with pemafibrate. Similarly, improvement of the blood lipid profile without any adverse changes of the hepatic or renal function parameters was also observed in patients who received prolonged combined pemafibrate+statin treatment. Thus, our findings confirm the safety and efficacy of pemafibrate administered either alone or in combination with a statin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Diabetes, Motor Function and Metabolism, Research Center of Health, Physical Fitness and Sports, Nagoya University, Chikusa-ku, Nagoya City, Aichi, Japan.
- Graduate School of Medicine, Department of Integrated Health Sciences, Nagoya University, Higashi-ku, Nagoya City, Aichi, Japan.
- Department of Data Science, Faculty of Science and Technology, Nanzan University, Showa-ku, Nagoya City, Aichi, Japan.
- Akishima Clinic, Naka-ku, Nagoya City, Japan.
- Okinaka Memorial Institute for Medical Research, Minato-ku, Tokyo, Japan.
- Office of Medical Education, School of Medicine, International University of Health and Welfare, Kozunomori, Narita City, Chiba, Japan.
Zitieren
APA
Kusunoki, M., Hisano, F., Matsuda, S. I., Kusunoki, A., Tsutsumi, K., & Miyata, T. (2025). Efficacy and Safety of Prolonged Treatment with Pemafibrate plus an HMG-CoA Reductase Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus. Drug Research, 75(07), 275-280. https://doi.org/10.1055/a-2560-9750
Vancouver
Kusunoki M, Hisano F, Matsuda SI, Kusunoki A, Tsutsumi K, Miyata T. Efficacy and Safety of Prolonged Treatment with Pemafibrate plus an HMG-CoA Reductase Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus. Drug Research. 2025;75(07):275-280. doi:10.1055/a-2560-9750
BibTeX
@article{Kusunoki2025,
author = {Kusunoki, Masataka and Hisano, Fumiya and Matsuda, Shin-Ichi and Kusunoki, Akiko and Tsutsumi, Kazuhiko and Miyata, Tetsuro},
title = {Efficacy and Safety of Prolonged Treatment with Pemafibrate plus an HMG-CoA Reductase Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus},
journal = {Drug Research},
year = {2025},
volume = {75},
number = {07},
pages = {275--280},
doi = {10.1055/a-2560-9750}
}
EUVIMED